Dosing of zoledronic acid throughout the treatment continuum in breast cancer

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 2, 2011, Pages 175-188

  Hadji, Peyman ^a   Gnant, Michael ^b   Aapro, Matti ^c   Lipton, Allan ^d   Coleman, Robert ^e  

^a UNIVERSITY HOSPITAL MARBURG   (Germany)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c Multidisciplinary Oncology Institute   (Switzerland)

^d PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^e WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

Anticancer activity; Aromatase inhibitor; Bisphosphonate dose; Bone loss; Bone metastasis; Bone turnover marker; Breast cancer; Zoledronic acid

Indexed keywords

ALENDRONIC ACID; ANASTROZOLE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; GOSERELIN; IBANDRONIC ACID; LETROZOLE; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; TAMOXIFEN; ZOLEDRONIC ACID;

BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER RISK; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SAFETY; EARLY CANCER; HUMAN; JAW OSTEONECROSIS; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; DRUG TOXICITY; FEMALE; HUMANS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; NEOPLASM STAGING; OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79960175587     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.017     Document Type: Review

References (113)

1. Garcia M., Jemal A., Ward E.M., et al. Global cancer facts & figures, 2007 2007, American Cancer Society, Atlanta, GA.
2. Coleman R.E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27:165-176.
3. Pfeilschifter J., Diel I.J. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol 2000, 18:1570-1593.
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
5. Winer E.P., Hudis C., Burstein H.J., et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23:619-629.
6. Pritchard K. Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women. Breast Cancer Res 2005, 7:70-76.
7. Goldhirsch A., Ingle J.N., Gelber R.D., Coates A.S., Thurlimann B., Senn H.J. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009. Ann Oncol 2009, 20:1319-1329.
8. Pouilles J.M., Tremollieres F., Ribot C. Effect of menopause on femoral and vertebral bone loss. J Bone Miner Res 1995, 10:1531-1536.
9. Hadji P. Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol 2009, 69:73-82.
10. Shapiro C.L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 2001, 19:3306-3311.
11. Fogelman I., Blake G.M., Blamey R., et al. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF). Osteoporos Int 2003, 14:1001-1006.
12. Gnant M., Mlineritsch B., Luschin-Ebengreuth G., et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol 2008, 9:840-849.
13. Vehmanen L., Elomaa I., Blomqvist C., Saarto T. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status. J Clin Oncol 2006, 24:675-680.
14. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25:486-492.
15. Eastell R., Adams J.E., Coleman R.E., et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008, 26:1051-1057.
16. Coleman R.E., Banks L.M., Girgis S.I., et al. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol 2007, 8:119-127.
17. Confavreux C.B., Fontana A., Guastalla J.P., Munoz F., Brun J., Delmas P.D. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates. Bone 2007, 41:346-352.
18. Coombes R.C., Kilburn L.S., Snowdon C.F., et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369:559-570.
19. Eastell R., Hannon R.A., Cuzick J., Dowsett M., Clack G., Adams J.E. Effect of an aromatase inhibitor on BMD and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230). J Bone Miner Res 2006, 21:1215-1223.
20. Lester J., Coleman R. Bone loss and the aromatase inhibitors. Br J Cancer 2005, 93(Suppl. 1):S16-S22.
21. Perez E.A., Josse R.G., Pritchard K.I., et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006, 24:3629-3635.
22. Pavlakis N., Schmidt R., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005, CD003474.
23. Bock O., Felsenberg D. Bisphosphonates in the management of postmenopausal osteoporosis-optimizing efficacy in clinical practice. Clin Interv Aging 2008, 3:279-297.
24. Kimmel D.B. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007, 86:1022-1033.
25. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007, 356:1809-1822.
26. Grey A., Bolland M.J., Wattie D., Horne A., Gamble G., Reid I.R. The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women. J Clin Endocrinol Metab 2009, 94:538-544.
27. Bartl R., Gotte S., Hadji P., Hammerschmidt T. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment. Dtsch Med Wochenschr 2006, 131:1257-1262.
28. Cooper A., Drake J., Brankin E. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006, 60:896-905.
29. Reginster J.Y. Adherence and persistence: impact on outcomes and health care resources. Bone 2006, 38(Suppl. 2):S18-S21.
30. Weiss T.W., Henderson S.C., McHorney C.A., Cramer J.A. Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills. Curr Med Res Opin 2007, 23:2193-2203.
31. Silverman S.L., Gold D.T. Compliance and persistence with osteoporosis therapies. Curr Rheumatol Rep 2008, 10:118-122.
32. Cole R.E., Harris S.T. Preventing nonvertebral osteoporotic fractures with extended-interval bisphosphonates: regimen selection and clinical application. Medscape J Med 2009, 11:12.
33. Downey T.W., Foltz S.H., Boccuzzi S.J., Omar M.A., Kahler K.H. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006, 99:570-575.
34. Ettinger M.P., Gallagher R., MacCosbe P.E. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006, 12:522-528.
35. Hadji P., Jackisch C., Blettner M., Harbeck N., Lueck H.-J., Krieienberg R. Oncology-non-compliance in the adjuvant, endocrine therapy of breast cancer. Senologie 2007, 4:69-72.
36. Ziller V., Kalder M., Albert U.S., et al. Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009, 20:431-436.
37. Hadji P. Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 2010, 73:156-166.
38. Kristensen B., Ejlertsen B., Groenvold M., Hein S., Loft H., Mouridsen H.T. Oral clodronate in breast cancer patients with bone metastases: a randomized study. J Intern Med 1999, 246:67-74.
39. Paterson A.H.G., Powles T.J., Kanis J.A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993, 11:59-65.
40. Robertson A.G., Reed N.S., Ralston S.H. Effect of oral clodronate on metastatic bone pain: a double-blind, placebo-controlled study. J Clin Oncol 1995, 13:2427-2430.
41. Hoer A., Gol D., Gothe H., Schiffhorst G., Brandman J., Haussler B. Rates and determinants of patient persistency with oral bisphosphonates in cancer patients. Support Care Cancer 2005, 13:428. [abstract 07-057].
42. Mangiapane S., Hoer A., Gothe H., Barghout V., Haeussler B. Higher persistency with i.v. bisphosphonates in patients with bone metastasis. J Clin Oncol 2006, 24(Suppl.):698s. [abstract 18623].
43. Fallowfield L., Jenkins V., Coleman R. Which bisphosphonates do oncologists prescribe for women with metastatic breast cancer and why? Results of a UK survey. Breast 2008, 17:459-463.
44. Hatoum H.T., Lin S.J., Smith M.R., Barghout V., Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008, 113:1438-1445.
45. Lipton A., Cook R., Saad F., et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008, 113:193-201.
46. Lipton A., Cook R.J., Major P., Smith M.R., Coleman R.E. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity. Oncologist 2007, 12:1035-1043.
47. Mystakidou K., Katsouda E., Parpa E., Kelekis A., Galanos A., Vlahos L. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005, 22:195-201.
48. Major P., Lortholary A., Hon J., et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001, 19:558-567.
49. Rosen L.S., Gordon D.H., Dugan W., et al. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004, 100:36-43.
50. Hershman D.L., McMahon D.J., Crew K.D., et al. Zoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol 2008, 26:4739-4745.
51. Swenson K.K., Nissen M.J., Anderson E., Shapiro A., Schousboe J., Leach J. Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy. J Support Oncol 2009, 7:101-107.
52. Shapiro C.L., Halabi S., Gibson G., et al. Effect of zoledronic acid (ZA) on bone mineral density (BMD) in premenopausal women who develop ovarian failure (OF) due to adjuvant chemotherapy (AdC); first results from CALGB trial 79809. J Clin Oncol 2008, 26(Suppl.):9s. [abstract 512].
53. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update. Semin Oncol 2006, 33(Suppl. 7):S13-S17.
54. Bundred N.J., Campbell I.D., Davidson N., et al. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST study results. Cancer 2008, 112:1001-1010.
55. Gnant M.F.X., Mlineritsch B., Luschin-Ebengreuth G., et al. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007, 25:820-828.
56. Schenk N., Llombart A., Frassoldati A., et al. The E-ZO-FAST trial: zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole (Let). Eur J Cancer Suppl 2007, 5:186-187. [abstract 2008].
57. Vehmanen L., Saarto T., Elomaa I., Makela P., Valimaki M., Blomqvist C. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer 2001, 37:2373-2378.
58. Delmas P.D., Balena R., Confravreux E., Hardouin C., Hardy P., Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol 1997, 15:955-962.
59. Hines S.L., Mincey B.A., Sloan J.A., et al. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 2009, 27:1047-1053.
60. Greenspan S.L., Brufsky A., Lembersky B.C., et al. Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial. J Clin Oncol 2008, 26:2644-2652.
61. Lester J.E., Dodwell D., Purohit O.P., et al. Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 2008, 14:6336-6342.
62. Van Poznak C., Hannon R.A., Mackey J.R., et al. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial. J Clin Oncol 2010, (January (11)). [Epub ahead of print].
63. Ibrahim A., Scher N., Williams G., et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 2003, 9:2394-2399.
64. Coleman R.E., Winter M.C., Cameron D., et al. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102:1099-1105.
65. Kohno N., Aogi K., Minami H., et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005, 23:3314-3321.
66. Rosen L.S., Gordon D., Kaminski M., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
67. Saad F., Lipton A., Cook R., Chen Y.-M., Smith M., Coleman R. Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110:1860-1867.
68. Brown J.E., Cook R.J., Major P., et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005, 97:59-69.
69. Schran H., Ravera C., Skerjanec A., Boisclair M. Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease. Presented at International Bone and Mineral Society Davos Workshops: Bone Biology and Therapeutics 2008, [abstract 199].
70. Skerjanec A., Berenson J., Hsu C., et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003, 43:154-162.
71. US National Institutes of Health. Comparison of two schedules of zoledronic acid in treating patients with breast cancer that has spread to the bone. ; 2009 [accessed 12.23.09]. http://www.clinicaltrials.gov/ct2/show/NCT00458796%3Fterm=BISMARK%26rank=2.
72. Lipton A., Body J.-J., Cook R., Coleman R. Prognosis and skeletal disease course in patients with bone metastases from breast cancer (BC) and normal baseline levels of N-telopeptide of type I collagen (NTX). Cancer Treat Rev 2008, (34Suppl.):S53. [abstract OC10].
73. Winter M.C., Holen I., Coleman R.E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34:453-475.
74. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9:45-53.
75. Brufsky A.M., Bosserman L.D., Caradonna R.R., et al. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9:77-85.
76. Eidtmann H., de Boer R., Bundred N., et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010.
77. Llombart A., Frassoldati A., Paija O., et al. Zoledronic acid prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: E-ZO-FAST 36-month follow-up. Presented at American Society of Clinical Oncology 2009 Breast Cancer Symposium 2009, [abstract 213].
78. Brufsky A., Bundred N., Coleman R., et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13:503-514.
79. Brown J.E., Ellis S.P., Lester J.E., et al. Prolonged efficacy of a single dose of the bisphosphonate zoledronic acid. Clin Cancer Res 2007, 13:5406-5410.
80. Frassoldati A., Brufsky A., Bundred N., et al. The effect of zoledronic acid on aromatase inhibitor (AI) associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24-months (mos) integrated follow-up of the Z-FAST and ZO-FAST trials. Presented at 33rd Congress of the European Society for Medical Oncology (ESMO). September 12-16 2008, [abstract 185PD].
81. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360:679-691.
82. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14:2738-2746.
83. Wiedswang G., Borgen E., Schirmer C., et al. Comparison of the clinical significance of occult tumor cells in blood and bone marrow in breast cancer. Int J Cancer 2006, 118:2013-2019.
84. Duivenvoorden W.C., Vukmirovic-Popovic S., Kalina M., Seidlitz E., Singh G. Effect of zoledronic acid on the doxycycline-induced decrease in tumour burden in a bone metastasis model of human breast cancer. Br J Cancer 2007, 96:1526-1531.
85. Jagdev S.P., Coleman R.E., Shipman C.M., Rostami H.A., Croucher P.I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001, 84:1126-1134.
86. Ottewell P.D., Deux B., Monkkonen H., et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clin Cancer Res 2008, 14:4658-4666.
87. Ottewell P.D., Monkkonen H., Jones M., Lefley D.V., Coleman R.E., Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100:1167-1178.
88. Senaratne S.G., Pirianov G., Mansi J.L., Arnett T.R., Colston K.W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82:1459-1468.
89. Neville-Webbe H.L., Coleman R.E., Holen I. Combined effects of the bisphosphonate, zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010, 102:1010-1017.
90. Aft R., Naughton M., Trinkaus K., et al. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11:421-428.
91. Lin A.Y., Park J.W., Scott J., et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol 2008, 26(Suppl.):20s. [abstract 559].
92. Rack B., Schindlbeck C., Strobl B., Sommer H., Friese K., Janni W. Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study. Dtsch Med Wochenschr 2008, 133:285-289.
93. Solomayer E.F., Gebauer G., Hirnle P., et al. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Cancer Res 2009, 69(Suppl.):170s-171s. [abstract 2048].
94. Coleman R.E., Thorpe H., Cameron D., et al. Zoledronic acid is well tolerated and can be safely administered with adjuvant chemotherapy-first safety data from the AZURE trial (BIG01/04). Presented at 29th Annual San Antonio Breast Cancer Symposium 2006, [abstract 2080].
95. Berenson J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005, 10:52-62.
96. Zometa® (zoledronic acid) Summary of Product Characteristics 2003, Novartis Europharm Limited, West Sussex, UK.
97. Estilo C.L., Van Poznak C.H., Wiliams T., et al. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist 2008, 13:911-920.
98. Hoff A.O., Toth B.B., Altundag K., et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008, 23:826-836.
99. Weitzman R., Sauter N., Eriksen E.F., et al. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007, 62:148-152.
100. Estilo C.L., Fornier M., Farooki A., Carlson D., Bohle G., Huryn J.M. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008, 26:4037-4038.
101. McArthur H.L., Estilo C., Huryn J., et al. Osteonecrosis of the jaw (ONJ) among intravenous (IV) bisphosphonate- and/or bevacizumab-treated patients at Memorial Sloan-Kettering Cancer Center (MSKCC). J Clin Oncol 2008, 26(Suppl.):523s. [abstract 9588].
102. Christodoulou C., Pervena A., Klouvas G., et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009, 76:209-211.
103. Lenz J.H., Steiner-Krammer B., Schmidt W., et al. Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?. J Craniomaxillofac Surg 2005, 33:395-403.
104. Dimopoulos M.A., Kastritis E., Bamia C., et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009, 20:117-120.
105. Ripamonti C.I., Maniezzo M., Campa T., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009, 20:137-145.
106. Montefusco V., Gay F., Spina F., et al. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma 2008, 49:2156-2162.
107. Badros A., Terpos E., Katodritou E., et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008, 26:5904-5909.
108. Mauri D., Valachis A., Polyzos I.P., Polyzos N.P., Kamposioras K., Pesce L.L. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta-analysis. Breast Cancer Res Treat 2009, 116:433-439.
109. Coleman R., Bundred N., de Boer R., et al. Impact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST. Presented at 32nd Annual San Antonio Breast Cancer Symposium 2009, [abstract 4082].
110. Burkinshaw R., Winter M., Thorpe H., Pedlar J., Coleman R. Osteonecrosis of the jaw and dental related adverse events during adjuvant therapy for early breast cancer: initial dental safety findings from the AZURE study. Presented at VII International Meeting on Cancer-Induced Bone Disease 2008, [abstract P53].
111. Fehm T., Felsenberg D., Hadji P., Krimmel M., Solomayer E., Wallwiener D. Bisphosphonat-assoziierte kieferosteonekrose bei mammakarzinompatientinnen: empfehlungen zur pravention und therapie. Geburtsch Frauenheilk 2009, 69:252-255.
112. Aapro M., Abrahamsson P.A., Body J.J., et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008, 19:420-432.
113. Hillner B.E., Ingle J.N., Chlebowski R.T., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.